A study presented at ACR Convergence 2025 has sparked interest among doctors and patients alike. Drugs originally made for ...

Current therapies such as biological DMARDs showed promising results in treating rheumatoid arthritis patients, and market penetration is expected to be more in the future and expected to drive market ...

Polypharmacy in RA patients is linked to increased drug interaction risks, especially with immunosuppressants, necessitating careful management and monitoring. Older age and multiple comorbidities are ...

Rheumatoid arthritis (RA) is a chronic autoimmune condition. The UM Faculty Physicians team is dedicated to helping you ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the ...

Belgian drugmaker Ablynx holds high hopes for its experimental drug to treat rheumatoid arthritis after seeing strong results in a recent clinical trial, according to Reuters. North Chicago, ...

In general, rheumatoid arthritis and higher BMI each increase risk for cardiovascular disease and events. This large cohort study suggested, however, that the relationship between BMI and ...

Rockville, MD - This week Genentech, Biogen, and Roche, the makers of rituximab, announced that they have applied to the US Food and Drug Administration for a new indication for the treatment of ...

San Diego, CA - Research in mice has shown that one of the pivotal pathways in inflammatory arthritis?the one involving p38 mitogen-activated protein kinase (MAPK)?can be blocked selectively, which ...